ALAUNOS THERAPEUTICS INC (TCRT)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$1.63-1.21%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · TCRT
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 652.8% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Elevated risk of a next-quarter earnings miss: this name is a smaller-cap name (higher miss base rate) and has been missing across recent quarters. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 399 industry peers · Company calendar date is not available
TCRT — legal / regulatory event — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standar…
Dated 2026-04-15
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On April 9, 2026, Alaunos Therapeutics, Inc. (the “Company”) received a written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that it is not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires listed companies to maintain a minimum of $2,500,000 in stockholders’ equity for continued listing on the…
Why it matters: A better formulation could make ALN1003 work better. This is key for its future.
Supportive ifManagement says they are working on the formulation. They are also studying it in large animals.
Worry ifNo news on formulation changes or delays in studies.
Why it matters: Solving these disputes could help partnerships and improve research work.
Supportive ifAn announcement confirms a settlement or new deal with MD Anderson.
Worry ifOngoing disputes or bad news in talks with MD Anderson may occur.
Why it matters: New partnerships could bring funding and resources. This is important for Alaunos' growth.
Supportive ifA press release says there is a new partnership or collaboration.
Worry ifNo new partnerships announced and still relying on current resources.
Why it matters: New data could show ALN1003 helps improve metabolic health. This is important for its use in clinics.
Supportive ifNew data shows ALN1003 lowers HOMA-IR scores in early studies.
Worry ifData shows no big change in insulin-resistance markers.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$158 on $10,000 · ±1.6% | How much price usually moves either way. |
| Bad day | $815 loss on $10,000 · 8.1% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $6,307 loss on $10,000 · 63.1% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: New data may show that ALN1003 works for metabolic disorders. This helps the company's plans.
Supportive ifA press release shows good results from the next study on ALN1003.
Worry ifA press release shows no improvement or bad results from the next study on ALN1003.
Why it matters: Improving the formulation could make ALN1003 work better. This is important for its growth.
Supportive ifManagement says they have changed ALN1003's formula and how it works in the body.
Worry ifManagement says they still have issues with the formula. No updates are available.
Why it matters: Creating new compounds could help Alaunos' patents and its market position.
Supportive ifA press release says next-generation compounds for ALN1003 have been successfully made.
Worry ifThere are no updates on the new compound development.
Why it matters: Updates on cash reserves are important. They help us see if the company can keep running.
Worry ifAn announcement of successful financing that extends the cash runway beyond Q2 2026.
Less concerning ifA report says cash reserves are low, which could hurt ongoing operations.
Why it matters: Staying compliant is important for the company's stock listing. Non-compliance can hurt investor trust.
Worry ifA notice says Alaunos is back in compliance with Nasdaq listing rules.
Less concerning ifA notice says the company is still not compliant with Nasdaq listing rules.
Why it matters: A strong cash position is necessary for ongoing research. New financing could support ALN1003's development.
Watch forManagement gets more funding to help with operations.
Also watch forManagement reports they could not get funding or face cash issues.
Why it matters: A successful financing could support ongoing development of ALN1003. This is critical given the current cash position.
Supportive ifManagement says they have secured funding that will last until 2026.
Worry ifManagement did not get funding, which may lead to problems in operations.
Why it matters: A compliance update will show if Alaunos can keep its listing. This affects investor confidence.
Worry ifA public announcement shows compliance with Nasdaq Listing Rule 5550(b)(1).
Less concerning ifAnother notice says the company may be delisted or is still not compliant with Nasdaq.